AN2 Therapeutics has signed an exclusive licence agreement with the University of Georgia Research Foundation to advance the development of a new boron-containing small molecule to treat Chagas disease.
The boron-based molecules were initially discovered by a team of researchers from Pfizer‘s wholly-owned subsidiary Anacor Pharmaceuticals and the University of Georgia, using non-dilutive grant funding from Wellcome.
The key compound in this series, AN2-502998, was discovered in partnership with Professor Rick Tarleton from the University of Georgia.
Wellcome has supported preclinical activities, carried out in collaboration with Tarleton.
AN2 Therapeutics co-founder, president and CEO Eric Easom stated: “AN2-502998 is the only compound to date that demonstrates complete cures of infection in non-human primates with long-term, naturally acquired chronic infections of diverse T cruzi genetic types.
“Professor Tarleton and scientists from AN2 have advanced this research, and with IND-enabling preclinical studies for AN2-502998 well underway and this licence in hand, we are excited to further develop AN2-502998 as a potential treatment for Chagas disease.”
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
The World Health Organisation (WHO) declared Chagas disease to be a neglected tropical disease.
It is caused by the Trypanosoma cruzi (T cruzi) parasite that spreads through a subspecies of blood-feeding insects commonly known as “kissing bugs.”
The WHO estimates that seven million people worldwide are infected with the parasite.
Source link
#AN2 #Therapeutics #receives #licence #develop #Chagas #therapy
